STERIS plc (STE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
STERIS plc stock (STE) is currently trading at $223.38. STERIS plc PE ratio is 31.15. STERIS plc PS ratio (Price-to-Sales) is 3.76. Analyst consensus price target for STE is $279.29. WallStSmart rates STE as Hold.
- STE PE ratio analysis and historical PE chart
- STE PS ratio (Price-to-Sales) history and trend
- STE intrinsic value — DCF, Graham Number, EPV models
- STE stock price prediction 2025 2026 2027 2028 2029 2030
- STE fair value vs current price
- STE insider transactions and insider buying
- Is STE undervalued or overvalued?
- STERIS plc financial analysis — revenue, earnings, cash flow
- STE Piotroski F-Score and Altman Z-Score
- STE analyst price target and Smart Rating
STERIS
📊 No data available
Try selecting a different time range
STE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · STERIS plc (STE)
STE trades 30% above its Graham fair value of $187.57, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
STERIS plc (STE) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, institutional own.. Fundamentals are solid but monitor weak areas for improvement.
STERIS plc (STE) Key Strengths (2)
98.76% of shares held by major funds and institutions
Large-cap company with substantial market presence
STERIS plc (STE) Areas to Watch (8)
Premium pricing at 3.1x book value
Modest revenue growth at 9.20%
Moderate profitability with room for improvement
Growth is fairly priced, not cheap, not expensive
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 3.76x sales
Solid earnings growth at 12.10%
Decent profitability, keeps $12 per $100 revenue
Supporting Valuation Data
STERIS plc (STE) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 2 register as strengths (avg 9.5/10) while 8 fall into concern territory (avg 5.4/10). All four categories (Growth, Profitability, Valuation, and Quality) show healthy scores, indicating broadly sound fundamentals.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap.
The Bear Case
The primary concerns are Price/Book, Revenue Growth, Return on Equity. Some valuation metrics including PEG Ratio (1.71), Price/Sales (3.76), Price/Book (3.06) suggest expensive pricing. Growth concerns include Revenue Growth at 9.20%, EPS Growth at 12.10%, which may limit upside. Profitability pressure is visible in Return on Equity at 10.50%, Operating Margin at 18.50%, Profit Margin at 12.10%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Book improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 10.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Institutional Own., Market Cap) and negatives (Price/Book, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
STE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
STE's Price-to-Sales ratio of 3.76x trades at a 32% premium to its historical average of 2.86x (87th percentile). The current valuation is 16% below its historical high of 4.46x set in Nov 2018, and 117% above its historical low of 1.73x in Apr 2009. Over the past 12 months, the PS ratio has compressed from ~4.3x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for STERIS plc (STE) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
STERIS plc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 5.8B with 9% growth year-over-year. Profit margins of 12.1% are healthy, with room for further expansion as the business scales.
Key Findings
Generating 200M in free cash flow and 298M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Margin expansion: can STERIS plc push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact STERIS plc.
Bottom Line
STERIS plc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About STERIS plc(STE)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Steris Corporation is an American Irish-domiciled medical equipment company specializing in sterilization and surgical products for the US healthcare system.